Insider Selling: Evolus, Inc. (NASDAQ:EOLS) CFO Sells 1,586 Shares of Stock

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver sold 1,586 shares of Evolus stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $10.85, for a total value of $17,208.10. Following the completion of the transaction, the chief financial officer now directly owns 146,916 shares of the company’s stock, valued at $1,594,038.60. This represents a 1.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Evolus Stock Performance

NASDAQ:EOLS opened at $11.09 on Friday. Evolus, Inc. has a twelve month low of $9.80 and a twelve month high of $17.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The stock’s 50-day simple moving average is $13.35 and its 200 day simple moving average is $13.73. The firm has a market capitalization of $702.23 million, a PE ratio of -12.19 and a beta of 1.27.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Evolus in a research report on Monday, September 16th. Barclays raised their target price on shares of Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Evolus in a report on Friday, September 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of Evolus in a research note on Thursday, November 7th.

Institutional Investors Weigh In On Evolus

A number of hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC acquired a new position in Evolus during the 2nd quarter worth approximately $3,906,000. Charles Schwab Investment Management Inc. grew its stake in shares of Evolus by 173.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock worth $6,781,000 after buying an additional 265,635 shares during the last quarter. Ikarian Capital LLC acquired a new position in shares of Evolus during the third quarter worth $4,184,000. Walleye Capital LLC bought a new position in shares of Evolus in the 3rd quarter valued at $3,438,000. Finally, Lord Abbett & CO. LLC boosted its holdings in shares of Evolus by 23.4% during the 3rd quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock valued at $16,126,000 after acquiring an additional 188,685 shares in the last quarter. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.